www.fdanews.com/articles/61340-biovest-international-receives-positive-opinion-on-application-for-orphan-medicinal-product-designation-by-european-agency
BIOVEST INTERNATIONAL RECEIVES POSITIVE OPINION ON APPLICATION FOR ORPHAN MEDICINAL PRODUCT DESIGNATION BY EUROPEAN AGENCY
August 1, 2006
Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., has received official notification from the Committee on Orphan Medical Products (COMP) of the European Medicines Agency that a positive opinion was made regarding the application for orphan medicinal product designation for BiovaxID the company's autologous immunotherapy for the treatment of follicular lymphoma in the European Union (EU).
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=3967512)